
As an Amazon Associate and affiliate partner, Menrva Books earns from qualifying purchases. Learn more
The remarkable story behind the revolutionary miracle cure for cancer, Gleevec. Novartis chairman Dr Dan Vasella describes its development and how he and Novartis orchestrated the break–neck approval and massive production of this amazing drug.Pharmaceutical giant Novartis recently developed Gleevec, one of the first 'smart' drugs created to kill cancer cells without damaging healthy cells in the process. In early tests with a common form of leukemia and other types of cancer, Gleevec has been extraordinarily successful, and side effects have been astoundingly minimal. Gleevec communicates directly with cancer–causing chromosomes and interrupts the signal that causes excessive growth of certain white blood cells. Patients have seen their tumours shrink significantly, and some have disappeared altogether.This is the inside story of the creation of this miracle drug, and how Novartis CEO and chairman Dan Vasella rallied the company to bring Gleevec to market in mass quantities and record time.
This book investigates the complex intersection of pharmaceutical research, corporate strategy, and regulatory navigation required to bring a targeted cancer therapy to market. Written by Dr. Daniel Vasella, the former CEO and chairman of Novartis, the text provides a firsthand account of the development of Gleevec, a drug designed to inhibit specific cancer-causing proteins. The narrative argues that the successful deployment of such a treatment requires not only scientific innovation but also a radical shift in organizational culture and aggressive management of the clinical trial and approval processes.
What You Will Find
Scope Limits
Readers and industry observers frequently note that the book serves as a valuable primary source for understanding the high-stakes environment of pharmaceutical leadership. Experts often highlight the text as a detailed case study in corporate management and the logistical challenges of bringing targeted therapies to patients.
Page Count:
288
Publication Date:
2003-06-01
Publisher:
Harper Business
ISBN-10:
0060010304
ISBN-13:
9780060010300
No comments yet. Be the first to share your thoughts!